@Article{,
AUTHOR = {Abdullah M. Al Ghamdi, Michael A. S. Jewett},
TITLE = {Stage I nonseminomatous germ cell tumors: the case for management by risk stratification},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {12},
YEAR = {2005},
NUMBER = {Suppl.1},
PAGES = {62--65},
URL = {http://www.techscience.com/CJU/v12nSuppl.1/63385},
ISSN = {1488-5581},
ABSTRACT = {For patients with clinical stage I nonseminomatous germ
cell tumor (NSGCT), the therapeutic options after
orchiectomy are retroperitoneal lymphadenectomy,
surveillance, and chemotherapy. Ideally the option
selected will be based on an individualized assessment of
the estimated risk of progression based on prognostic
factors, so called risk-adapted treatment, to reduce overall
burden of therapy while maintaining survival. It is
possible to identify patients at low risk of progression
who can be followed by active surveillance initially.
Prognostic factors for high risk, while well defined, do
not identify all patients at risk and those that are destined
to progress, can usually be salvaged with delayed therapy.
Most centres recommend either surgery or primary
chemotherapy for those defined as being at high risk for
progression. Prognostic factors for high risk however,
while well defined, do not identify all patients at risk and
those that are destined to progress, can usually be salvaged
with delayed therapy.},
DOI = {}
}